FDA schedules meeting to review Cartiva’s PMA for synthetic cartilage implant: 4 points

The FDA has tentatively scheduled a meeting of the Orthopaedic and Rehabilitation Devices Panel to review Cartiva’s premarket approval application for its Cartiva Synthetic Cartilage Implant.

Advertisement

Here are four points:

 

1. The meeting is slated to take place on April 20.

 

2. The implant is intended for the treatment of osteoarthritis at the base of the big toe.

 

3. The FDA recently completed a five-day inspection of Cartiva’s Alpharetta, Ga., facility and reported no issues.

 

4. Cartiva is a developer of products for the treatment of cartilage injuries, osteoarthritis and other musculoskeletal conditions.

 

More articles on devices:
Smith & Nephew, Zimmer Biomet, Medovex & more: 20 key notes
Global non-fusion spinal device market to grow: 3 points
Medtech sells 2 ROSA Brain robots in US: 3 quick notes

At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.

Advertisement

Next Up in Spinal Tech

Advertisement

Comments are closed.